205 related articles for article (PubMed ID: 25613565)
1. Autologous Hematopoietic Stem Cells transplantation and genetic modification of CCR5 m303/m303 mutant patient for HIV/AIDS.
Esmaeilzadeh A; Farshbaf A; Erfanmanesh M
Med Hypotheses; 2015 Mar; 84(3):216-8. PubMed ID: 25613565
[TBL] [Abstract][Full Text] [Related]
2. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
3. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
[TBL] [Abstract][Full Text] [Related]
5. Editing CCR5: a novel approach to HIV gene therapy.
Cornu TI; Mussolino C; Bloom K; Cathomen T
Adv Exp Med Biol; 2015; 848():117-30. PubMed ID: 25757618
[TBL] [Abstract][Full Text] [Related]
6. CCR5 as a natural and modulated target for inhibition of HIV.
Burke BP; Boyd MP; Impey H; Breton LR; Bartlett JS; Symonds GP; Hütter G
Viruses; 2013 Dec; 6(1):54-68. PubMed ID: 24381033
[TBL] [Abstract][Full Text] [Related]
7. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene.
Quillent C; Oberlin E; Braun J; Rousset D; Gonzalez-Canali G; Métais P; Montagnier L; Virelizier JL; Arenzana-Seisdedos F; Beretta A
Lancet; 1998 Jan; 351(9095):14-8. PubMed ID: 9433423
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.
Solloch UV; Lang K; Lange V; Böhme I; Schmidt AH; Sauter J
Hum Immunol; 2017 Nov; 78(11-12):710-717. PubMed ID: 28987960
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in CCR5 regulation for HIV cure.
Garg K; Khan AR; Taneja P
Adv Protein Chem Struct Biol; 2021; 126():123-149. PubMed ID: 34090613
[TBL] [Abstract][Full Text] [Related]
10. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.
Li L; Krymskaya L; Wang J; Henley J; Rao A; Cao LF; Tran CA; Torres-Coronado M; Gardner A; Gonzalez N; Kim K; Liu PQ; Hofer U; Lopez E; Gregory PD; Liu Q; Holmes MC; Cannon PM; Zaia JA; DiGiusto DL
Mol Ther; 2013 Jun; 21(6):1259-69. PubMed ID: 23587921
[TBL] [Abstract][Full Text] [Related]
11. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.
Mulherin SA; O'Brien TR; Ioannidis JP; Goedert JJ; Buchbinder SP; Coutinho RA; Jamieson BD; Meyer L; Michael NL; Pantaleo G; Rizzardi GP; Schuitemaker H; Sheppard HW; Theodorou ID; Vlahov D; Rosenberg PS;
AIDS; 2003 Feb; 17(3):377-87. PubMed ID: 12556692
[TBL] [Abstract][Full Text] [Related]
12. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects.
Lai Y
Curr Stem Cell Res Ther; 2012 Jul; 7(4):310-7. PubMed ID: 22486585
[TBL] [Abstract][Full Text] [Related]
13. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
14. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
15. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
Li H; Liu TJ; Hong ZH
Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
[TBL] [Abstract][Full Text] [Related]
16. HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
Ballana E; Riveira-Munoz E; Pou C; Bach V; Parera M; Noguera M; Santos JR; Badia R; Casadellà M; Clotet B; Paredes R; Martínez MA; Brander C; Esté JA
Immunobiology; 2013 Apr; 218(4):543-7. PubMed ID: 22818666
[TBL] [Abstract][Full Text] [Related]
17. Potential mechanisms for cell-based gene therapy to treat HIV/AIDS.
Herrera-Carrillo E; Berkhout B
Expert Opin Ther Targets; 2015 Feb; 19(2):245-63. PubMed ID: 25388088
[TBL] [Abstract][Full Text] [Related]
18. From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation.
Prator CA; Donatelli J; Henrich TJ
Curr HIV/AIDS Rep; 2020 Aug; 17(4):385-393. PubMed ID: 32519184
[TBL] [Abstract][Full Text] [Related]
19. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of a 32 bp deletion in the gene for human immunodeficiency virus 1 co-receptor CCR5 in Slovak population.
Takácová M; Nogová P; Hábeková M; Staneková D
Acta Virol; 2008; 52(4):261-4. PubMed ID: 19143484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
